MannKind Corporation develops and commercializes innovative therapeutic products and devices for people living with endocrine and orphan lung diseases.

MannKind Corporation

Immix Biopharma, Inc., a clinical-stage biopharmaceutical company, engages in developing various tissue-specific therapeutics in oncology and inflammation in the United States and Australia. The company is developing IMX-110 that is in Phase 1b/2a clinical trials for the treatment of soft tissue sarcoma and solid tumors; IMX-111, a tissue-specific biologic for the treatment of colorectal cancers; and IMX-120, a tissue-specific biologic for the treatment of ulcerative colitis and severe Crohn's disease. It has a clinical collaboration and supply agreement with BeiGene Ltd. for a combination Phase 1b clinical trial in solid tumors of IMX-110 and anti-PD-1 Tislelizumab. The company was incorporated in 2012 and is headquartered in Los Angeles, California.

Sean Senn

Ilya Rachman

Vladimir Torchilin

Immix Biopharma, Inc.

Millstone Medical Outsourcing provides post-manufacturing services to medical device manufacturers, focusing on packaging, testing, and logistics in order to improve quality and compliance.

Millstone Medical Outsourcing

NRX Pharmaceuticals, Inc., a clinical-stage pharmaceutical company, develops novel therapeutics for the treatment of central nervous system disorders and life-threatening pulmonary diseases. Its products include ZYESAMI, an investigational drug that has completed a Phase IIb/III clinical study for COVID-19 related respiratory failure; and NRX-100 and NRX-101 oral therapeutics for the treatment of bipolar depression in patients with acute suicidal behavior/ideation and sub-acute suicidal ideation and behavior. The company was founded in 2015 and is based in Wilmington, Delaware.

Metric
Company Name	MannKind Corporation	Immix Biopharma, Inc.	Millstone Medical Outsourcing	NRx Pharmaceuticals, Inc.
Symbol		IMMX		NRXP
MSH ID	COM:VALERITAS	COM:IMMIXBIO	COM:MILLSTONEMEDICAL	COM:NRXPHARMA
Market	PRIVATE	STOCKS	PRIVATE	STOCKS
Sector	Healthcare & Health Services	Healthcare	Healthcare & Health Services	Healthcare
Industry	Biotechnology	Biotechnology	Medical Device Manufacturing	Biotechnology
Country	US	US	US	US
Stage
Employee Count		14		2
Website	valeritas.com	immixbio.com	millstonemedical.com	nrxpharma.com
LinkedIn		immix-biopharma		nrx-pharma
Founders

Metric
Market Cap	53.89M		25.25M
Enterprise Value
Monthly Web Traffic		1.59K
Web Traffic Growth		-0.40
Valuation
Raised Capital

Metric
Revenue
Revenue (LTM)
Revenue (NTM)
Gross Profit
EBITDA
Operating Income
Net Income
EPS
Diluted EPS
Revenue 2022
Revenue 2023
Revenue 2024
Revenue 2025
Revenue 2026

Metric
Revenue Growth (LTM)
Revenue Growth (NTM)
Gross Profit Growth (LTM)
EBITDA Growth (LTM)
Net Income Growth (LTM)
14-Day Growth Score
28-Day Growth Score
90-Day Growth Score
365-Day Growth Score

Metric
Gross Profit Margin
Operating Profit Margin
EBITDA Margin
Net Profit Margin
Return on Equity
Return on Assets
Return on Capital Employed

COM:VALERITAS

MannKind Corporation

Company Overview

Market Metrics

Financial Performance

Growth Metrics

Profitability Ratios

Valuation Multiples

Operational Metrics

Cash Flow Metrics

Balance Sheet Metrics

Efficiency Metrics

Metric
P/E Ratio
P/B Ratio
Revenue Multiple (LTM)
Revenue Multiple (NTM)
EBITDA Multiple (LTM)
EBITDA Multiple (NTM)
Price to Sales Ratio
EV Multiple

Metric
Days Sales Outstanding
Days Payables Outstanding
Days Inventory Outstanding
Operating Cycle
Cash Conversion Cycle
Asset Turnover

Metric
Operating Cash Flow
Free Cash Flow
Cash Flow to Debt
Operating Cash Flow/Sales
Free Cash Flow Yield

Metric
Cash & Equivalents
Accounts Receivable
Inventory
Goodwill
Debt to Capitalization
Debt to Assets
Current Ratio
Quick Ratio

Metric
Rule of 40 (LTM)
Rule of 40 (NTM)
Stock Comp to Revenue
R&D to Revenue
SG&A to Revenue